2008   2007   2006   2005   2004   Upcoming Events  
  Home > News & Events  
   UPCOMING EVENTS
 

No upcoming events.

   PAST EVENTS
  BIO International Convention
San Diego Convention Center, San Diego, CA; June 17-20, 2008
 

Canaccord Adams Diabetes & Obesity Conference
Hotel Nikko, San Francisco, CA; June 6, 2008

  Bank of America 37th Annual Investment Conference
The Ritz-Carlton, San Francisco, CA; September 17-19, 2007
  The 6th Annual JMP Securities Research Conference
The Ritz-Carlton, San Francisco, CA; May 21-23, 2007
  BIO International Convention
Boston Convention & Exhibition Center, Boston, MA; May 6-9, 2007
  Future Leaders in the Biotech Industry
Millennium Broadway Hotel, New York City, NY; March 29, 2007
  BioCEO & Investor Conference
The Waldorf Astoria Hotel, New York City, NY; February 12-14, 2007
  JP Morgan 25th Annual Health Care Conference
Westin St. Francis, San Francisco, CA; January 8-11, 2007
   2008 NEWS
 
METABOLEX COMPLETES PATIENT ENROLLMENT IN PHASE 2 TRIAL OF MBX-8025 FOR TREATMENT OF DYSLIPIDEMIA
June 16, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides.
    More >
 
METABOLEX APPOINTS DONALD HILL AS CHIEF FINANCIAL OFFICER
April 14, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Donald M. Hill has joined the company as chief financial officer. Mr. Hill brings extensive financial and strategic planning experience to Metabolex, including expertise in business development, treasury management and controllership of large operating divisions...
    More >
 
METABOLEX INITIATES PHASE 1 TRIAL OF MBX-2982
March 26, 2008
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has dosed the first cohort of healthy subjects in a Phase 1 clinical trial of MBX-2982, a potential first-in-class treatment for type 2 diabetes ...
    More >